Sysmex : Financial Statements( PDF format / 292KB )

February 12, 2026

Listed company name : Sysmex Corporation

Code : 6869

Listed stock exchanges : Tokyo Stock Exchange

URL : https://www.sysmex.co.jp/en

Company representative : Kaoru Asano, President

Contact : Takuro Minami, Executive Vice President of Corporate Business Administration

Phone : 078(265)-0500

Scheduled date for dividend payment : -

Preparation of supplementary material for quarterly earnings

: Yes

Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Nine Months of the Fiscal Year Ending March 31, 2026

   1. Operating results

      (% changes as compared with the corresponding period of the previous fiscal year)

      	Net Sales		Operating profit		Profit before tax		Profit
      Nine months ended Dec. 31, 2025	361,168	(1.6)%	48,657	(27.7)%	47,471	(23.2)%	33,522	(21.1)%
      Nine months ended Dec. 31, 2024	366,866	12.4%	67,345	24.2%	61,792	20.9%	42,497	23.2%

      	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
      Nine months ended Dec. 31, 2025	33,694	(20.9)%	60,121	23.7%	54.05	54.05
      Nine months ended Dec. 31, 2024	42,615	23.7%	48,586	1.9%	68.35	68.33

   2. Financial condition

   	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
   As of Dec. 31, 2025	698,249	501,429	500,842	71.7%
   As of Mar. 31, 2025	665,268	464,534	463,776	69.7%

2. Dividend

   	Dividend per share
   	First quarter	Second quarter	Third quarter	Year-end	Annual
   	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)
   Year ended Mar. 31, 2025	￣	15.00	￣	17.00	32.00
   Year ending Mar. 31, 2026	￣	19.00	￣
   Year ending Mar. 31, 2026				19.00	38.00
   (Forecast)

   Notes: 1. Revision of dividends forecast for this period: No

   2. Details of the dividends for the fiscal year ending March 31, 2026 Second quarter Ordinary dividend: ¥18.00

   Commemorative dividend: ¥1.00 (30th anniversary of listing) Year-end Ordinary dividend: ¥18.00

   Commemorative dividend: ¥1.00 (30th anniversary of listing)

3. Financial Forecast for the Year Ending March 31, 2026

   (% changes as compared with the previous fiscal year)

   	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
   Year ending Mar. 31, 2026	500,000	(1.7)%	62,000	(29.2)%	59,000	(25.5)%	41,000	(23.6)%	65.77

   Note: Revision of financial forecast for this period: Yes

4. Other Information

1. Significant changes in scope of consolidation: No

2. Changes in accounting policies and accounting estimates

   1. Changes in accounting policies required by IFRS: No

   2. Other changes in accounting policies: No

   3. Changes in accounting estimates: No

3. Number of outstanding stock (common stock)

   1. Number of outstanding stock at the end of each fiscal period (including treasury stock): 629,480,076 shares as of Dec. 31, 2025; 629,473,176 shares as of Mar. 31, 2025

   2. Number of treasury stock at the end of each fiscal period:

      6,300,045 shares as of Dec. 31, 2025; 5,873,371 shares as of Mar. 31, 2025

   3. Average number of outstanding stock for each period (cumulative):

623,393,669 shares for the nine months ended Dec. 31, 2025 623,514,070 shares for the nine months ended Dec. 31, 2024

Note: The Company has introduced Executive Compensation BIP Trust and Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

• Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes (optional)

• Explanation regarding the appropriate use of financial forecast and other information

  1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within "1. Qualitative information on quarterly financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.

  2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Thursday, February 12, 2026.

1. Qualitative information on quarterly financial results 2

   1. Operating performance analysis 2

   2. Financial conditions analysis 3

   3. Consolidated financial forecast 4

   4. Operating risks 4

   5. Business and financial issues to be addressed 4

   6. Important management contracts, etc. 4

2. Condensed quarterly consolidated financial statements and notes 5

   1. Condensed quarterly consolidated statement of financial position 5

   2. Condensed quarterly consolidated statement of income 7

   3. Condensed quarterly consolidated statement of comprehensive income 8

   4. Condensed quarterly consolidated statement of changes in equity 9

   5. Condensed quarterly consolidated statement of cash flows 10

   6. Notes to the condensed quarterly consolidated financial statements 11

      1. Key considerations on the basis for the preparation of condensed quarterly consolidated 11

         financial statements

      2. Notes related to the going concern assumption 11

      3. Segment information 11

1. Qualitative information on quarterly financial results

   Future-related information contained in the text below is based on the Company's judgement as of

   the end of the fiscal period under review.

   1. Operating performance analysis

      The Group's consolidated financial results for the first nine months of the fiscal year ending March 31, 2026 are as follows.

      Net sales by destination

      		Nine months ended December 31, 2024		Nine months ended December 31, 2025		YoY (Previous period = 100)
      		Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)
      Japan		47,190	12.9	40,509	11.2	85.8
      	Americas	96,425	26.3	100,829	27.9	104.6
      	EMEA (Europe, the Middle East, and Africa)	102,871	28.0	114,909	31.8	111.7
      	China	82,000	22.3	65,533	18.2	79.9
      	AP (Asia Pacific)	38,378	10.5	39,386	10.9	102.6
      Overseas subtotal		319,675	87.1	320,659	88.8	100.3
      Total		366,866	100.0	361,168	100.0	98.4

      In Japan, we experienced lower sales of hematology instruments and reagents, as well as immunochemistry reagents. As a result, sales in Japan fell 14.2% year on year, to ¥40,509 million, and the sales ratio decreased 1.7 percentage points, to 11.2%.

      Overseas, sales of reagents in the hemostasis and immunochemistry fields decreased. However, instrument sales rose in the urinalysis and other fields. Accordingly, overseas sales rose 0.3%, to

      ¥320,659 million, and the overseas sales ratio increased 1.7 percentage points, to 88.8%.

      Selling, general and administrative (SG&A) expenses totaled ¥120,206 million, up 9.3% year on year, due primarily to an increase in personnel associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to

      ¥20,444 million, down 9.3%.

      As a result, on a consolidated basis for the first nine months of the fiscal year ending March 31, 2026, net sales amounted to ¥361,168 million (down 1.6% year on year), operating profit was

      ¥48,657 million (down 27.7%), profit before tax was ¥47,471 million (down 23.2%), and profit attributable to owners of the parent totaled ¥33,694 million (down 20.9%).

      Performance by segment

      1. Headquarters

         In South Korea, hematology instruments grew, but in Japan sales of hematology instruments and reagents decreased, as did sales of immunochemistry reagents. In the medical robotics business, sales of maintenance services grew, but sales of instruments decreased. Consequently, sales fell 8.9% year on year, to ¥60,580 million.

         On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥19,043 million (down 55.1%).

      2. Americas RHQ

         In North America, sales rose for hematology instruments and reagents, as well as for urinalysis instruments and maintenance services. In Central and South America, sales of urinalysis instruments and reagents increased. As a result, sales in the Americas were up 5.0% year on year, to ¥95,061 million.

         On the profit front, higher sales and other factors pushed up segment profit (operating profit) 16.4% year on year, to ¥6,289 million.

      3. EMEA RHQ

         In the hematology field, sales of instruments and reagents grew, mainly in the region's key countries. Sales of instruments in the urinalysis and other fields also increased, bolstering sales for the region by 11.7% year on year, to ¥111,082 million.

         Higher sales and an improved cost of sales ratio pushed up segment profit (operating profit) 13.5% year on year, to ¥8,864 million.

      4. China RHQ

         Operating in a difficult business environment affected by policies to curtail medical expenses, we experienced significant sales declines in hematology instruments and reagents, as well as hemostasis reagents. As a result, segment sales were ¥65,414 million, down 20.1% year on year.

         Although lower SG&A expenses had a positive impact on profit, lower sales caused segment profit (operating profit) to fall 9.3% year on year, to ¥7,467 million.

      5. Asia Pacific RHQ

         Reagent sales increased in the hemostasis and urinalysis fields. In the hematology field, sales of instruments and maintenance services decreased, while reagent sales grew. Accordingly, sales expanded by 1.7%, to ¥29,027 million.

         Despite the higher sales, segment profit (operating profit) decreased 16.5%, to ¥4,649 million, as the cost of sales ratio deteriorated owing to such factors as depreciation on our new production site in India, which was completed in August 2024.

   2. Financial conditions analysis

      1. Financial conditions

         As of December 31, 2025, total assets amounted to ¥698,249 million, up ¥32,980 million from their level on March 31. Among major factors, cash and cash equivalents were down ¥13,809 million, whereas inventories increased by ¥17,555 million, property, plant and equipment by

         ¥14,632 million. Among non-current assets, trade and other receivables expanded ¥5,473 million.

         Meanwhile, total liabilities decreased by ¥3,914 million from March 31, 2025, to ¥196,820 million. Key changes included a ¥6,647 million rise in non-current lease liabilities and ¥1,716 million higher contract liabilities. Meanwhile, income taxes payable declined by ¥8,591 million, and accrued bonuses by ¥4,516 million.

         Total equity increased by ¥36,894 million from March 31, 2025, to ¥501,429 million. Among principal reasons, other components of equity increased ¥26,640 million and retained earnings increased ¥11,211 million. The equity attributable to owners of the parent to total assets rose 2.0 percentage points, from 69.7% as of March 31, 2025, to 71.7%.

      2. Cash flows

         As of December 31, 2025, cash and cash equivalents amounted to ¥75,760 million, down

         ¥13,809 million from March 31, 2025.

         Cash flows from various activities during the first nine months of the fiscal year are described in more detail below.

         (Cash flows from operating activities)

         Net cash provided by operating activities was ¥50,044 million, down ¥8,878 million from the first nine months of the preceding fiscal year. As principal factors, profit before tax provided

         ¥47,471 million (¥14,321 million less than in the corresponding period of the preceding fiscal year), depreciation and amortization provided ¥34,820 million (up ¥6,119 million), a decrease in trade receivables provided ¥13,342 million (up ¥4,306 million), an increase in inventories used ¥12,602 million (up ¥210 million), and income taxes paid used ¥26,457 million (up ¥1,562 million).

         (Cash flows from investing activities)

         Net cash used in investing activities was ¥37,560 million (up ¥3,414 million). Among major factors, purchases of property, plant and equipment used ¥22,191 million (up ¥4,493 million), and purchases of intangible assets used ¥13,549 million (down ¥2,513 million).

         (Cash flows from financing activities)

         Net cash used in financing activities was ¥32,705 million (up ¥10,184 million). This was mainly

         due to dividends paid of ¥22,441 million (up ¥4,360 million), and repayments of lease liabilities of

         ¥8,925 million (up ¥1,232 million).

   3. Consolidated financial forecast

      For the Company's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Notice of Revision to the Full-Year Financial Forecast, announced today (February 12, 2026).

   4. Operating risks

      In the first nine months under review, no new operating risk emerged, and there were no material changes to the operating risks outlined in our financial report for the previous fiscal year.

   5. Business and financial issues to be addressed

      There are no significant changes to the descriptions of "Priority business and financial issues to be addressed" in "Part I: Corporate Information, Section 2: Business Overview, 1. Management Policy, Management Environment and Issues to be Addressed" in the financial report for the previous fiscal year.

   6. Important management contracts, etc.

      No conclusions of important management contracts or decisions regarding them were made during the first nine months under review.

2. Condensed quarterly consolidated financial statements and notes

   1. Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

Assets

Current assets

As of March 31, 2025

As of December 31, 2025

(Unit: Millions of yen)

Liabilities and equity

As of March 31, 2025

As of December 31, 2025

1. Condensed quarterly consolidated statement of comprehensive income

   (Unit: Millions of yen)

   Nine months ended December 31, 2024

   Nine months ended December 31, 2025

   Profit 42,497 33,522

   Other comprehensive income

   Items that will not be reclassified subsequently to profit or loss

   Net gain (loss) on financial assets measured at fair value through other	(1,401)	958
   comprehensive income
   Total	(1,401)	958

   Items that may be reclassified subsequently to profit or loss

   Exchange differences on translation of foreign operations Share of other comprehensive income of investments accounted for using	7,482 8	25,602 37
   the equity method
   Total	7,490	25,640
   Total other comprehensive income	6,089	26,598
   Comprehensive income	48,586	60,121
   Comprehensive income attributable to Owners of the parent	48,705	60,292
   Non-controlling interests	(118)	(171)
   Comprehensive income	48,586	60,121

2. Condensed quarterly consolidated statement of changes in equity Nine months ended December 31, 2024

   (Unit: Millions of yen)

   Equity attributable to owners Capital Capital Retained Treasury stock surplus earnings stock					of the parent Non- Other controlling Total components Total interests equity of equity
   As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
   Profit	-	-	42,615	-	-	42,615	(118)	42,497
   Other comprehensive income	-	-	-	-	6,089	6,089	-	6,089
   Comprehensive income	-	-	42,615	-	6,089	48,705	(118)	48,586
   Exercise of warrants	121	69	-	-	-	191	-	191
   Share-based payment transactions	-	27	-	-	-	27	-	27
   Cash dividends	-	-	(18,081)	-	-	(18,081)	-	(18,081)
   Purchase of treasury stock	-	-	-	(2)	-	(2)	-	(2)
   Disposal of treasury stock	-	0	-	0	-	0	-	0
   Transfer to retained earnings	-	-	1,361	-	(1,361)	-	-	-
   Total transactions with the owners	121	97	(16,720)	(2)	(1,361)	(17,864)	-	(17,864)
   As of December 31, 2024	14,851	20,928	391,881	(12,318)	47,542	462,885	733	463,618

   Nine months ended December 31, 2025

   (Unit: Millions of yen)

   Equity attributable to owners Capital Capital Retained Treasury stock surplus earnings stock					of the parent Non- Other controlling Total components Total interests equity of equity
   As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
   Profit	-	-	33,694	-	-	33,694	(171)	33,522
   Other comprehensive income	-	-	-	-	26,598	26,598	-	26,598
   Comprehensive income	-	-	33,694	-	26,598	60,292	(171)	60,121
   Exercise of warrants	10	6	-	-	-	16	-	16
   Share-based payment transactions	-	75	-	-	-	75	-	75
   Cash dividends	-	-	(22,441)	-	-	(22,441)	-	(22,441)
   Purchase of treasury stock	-	-	-	(877)	-	(877)	-	(877)
   Disposal of treasury stock	-	(31)	-	31	-	-	-	-
   Transfer to retained earnings	-	-	(41)	-	41	-	-	-
   Total transactions with the owners	10	50	(22,483)	(846)	41	(23,226)	-	(23,226)
   As of December 31, 2025	14,898	21,011	414,032	(13,165)	64,066	500,842	586	501,429

3. Condensed quarterly consolidated statement of cash flows

   (Unit: Millions of yen)

   Cash flows from operating activities

   Nine months ended December 31, 2024

   Nine months ended December 31, 2025

   Profit before tax 61,792 47,471

   Depreciation and amortization 28,700 34,820

   Share of loss (profit) of associates accounted for using the equity method	1,727	1,249
   Loss on retirement of non-current assets	166	620
   Decrease (increase) in trade receivable	9,036	13,342
   Decrease (increase) in advance payments	458	(1,021)
   Decrease (increase) in inventories	(12,391)	(12,602)
   Increase (decrease) in trade payable	111	280
   Increase (decrease) in accounts payable-other	(1,721)	(1,040)
   Increase (decrease) in contract liabilities	865	511
   Increase (decrease) in accrued expenses	681	(892)
   Decrease/increase in consumption taxes receivable/payable	(741)	330
   Increase (decrease) in accrued bonuses	(2,479)	(4,867)
   Other－net	(1,579)	(569)
   Subtotal	84,628	77,634
   Interest and dividend received	474	471
   Interest paid	(1,285)	(1,603)
   Income taxes paid	(24,895)	(26,457)
   Net cash provided by (used in) operating activities	58,922	50,044
   Cash flows from investing activities
   Purchases of property, plant and equipment	(17,697)	(22,191)
   Purchases of intangible assets	(16,063)	(13,549)
   Payments resulting in an increase in long-term prepaid expenses	(626)	(758)
   Purchases of investments in equity instruments	(2,008)	(254)
   Proceeds from the sale of equity instruments	1,853	0
   Purchase of investments in debt instruments	(399)	(978)
   Payments into time deposits	(1,306)	(977)
   Proceeds from withdrawal of time deposits	1,591	893
   Other－net	510	255
   Net cash provided by (used in) investing activities	(34,146)	(37,560)
   Cash flows from financing activities
   Proceeds from long-term loans payable	3,500	-
   Repayments of long-term loans payable	(435)	(508)
   Exercise of warrants	191	16
   Purchase of treasury shares	(2)	(877)
   Dividends paid	(18,081)	(22,441)
   Repayments of lease liabilities	(7,692)	(8,925)
   Other－net	0	31
   Net cash provided by (used in) financing activities	(22,520)	(32,705)
   Effects of exchange rate changes on cash and cash equivalents	4,177	6,412
   Net increase (decrease) in cash and cash equivalents	6,432	(13,809)
   Cash and cash equivalents at the beginning of the term	75,507	89,570
   Cash and cash equivalents at the end of the term	81,940	75,760

4. Notes to the condensed quarterly consolidated financial statements

   1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements

      The condensed quarterly consolidated financial statements have been prepared in accordance

      with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some disclosures in International Accounting Standard No. 34 "Interim Financial Reporting" are omitted.)

   2. Notes related to the going concern assumption Not applicable

   3. Segment information

      1. Overview of reportable segments

         The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

         The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

         The five managing company-specific segments are "Headquarters," "Americas RHQ," "EMEA RHQ," "China RHQ," and "AP RHQ."

         The companies included in these reportable segments are outlined below.

         Reportable segments	Companies included in the reportable segments
         Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
         Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
         EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
         China RHQ	Sysmex Shanghai ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
         AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

      2. Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows;

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting

policies indicated in the consolidated financial statements for the previous fiscal year.

Nine months ended December 31, 2024

(Unit: Millions of yen)

Notes: 1. Segment profit (loss) adjustments of negative ¥2,116 million include negative ¥1,880 million for the unrealized gains on inventories and negative ¥236 million for the unrealized gains on non-current assets.

2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

Nine months ended December 31, 2025

(Unit: Millions of yen)

Notes: 1. Segment profit (loss) adjustments of ¥2,342 million include ¥2,269 million for the unrealized gains on inventories and ¥72 million for the unrealized gains on non-current assets.

2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

- 13 －